| scholarly article | Q13442814 |
| P50 | author | Patrick M Reeves | Q57129045 |
| Ann Chahroudi | Q89143357 | ||
| P2093 | author name string | Darren Veach | |
| William Bornmann | |||
| Daniel Kalman | |||
| Mark B Feinberg | |||
| Rahul Chavan | |||
| Jens Christensen | |||
| Alyson Swimm | |||
| Melanie Sherman | |||
| Bettina Bommarius | |||
| Shannon McNulty | |||
| Sarah Lebeis | |||
| P2860 | cites work | Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus | Q42601218 |
| Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus | Q42823574 | ||
| Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. | Q43775891 | ||
| Vaccinia virus cores are transported on microtubules | Q44548913 | ||
| Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration | Q45723808 | ||
| Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. | Q45746416 | ||
| An antigenic difference between intracellular and extracellular rabbitpox virus | Q45827342 | ||
| Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination | Q47395264 | ||
| Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells | Q48042079 | ||
| Bacterial resistance to antimicrobial agents--the time for concern | Q72634759 | ||
| Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors | Q74271438 | ||
| Chronic myelogenous leukemia | Q77292029 | ||
| Structural basis for selective inhibition of Src family kinases by PP1 | Q78192599 | ||
| Diarrheagenic Escherichia coli | Q24533466 | ||
| Detection of other microbial species by Salmonella: expression of the SdiA regulon | Q24542448 | ||
| Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 | ||
| A complex of N-WASP and WIP integrates signalling cascades that lead to actin polymerization | Q28139787 | ||
| Essential roles for the Abl and Arg tyrosine kinases in neurulation | Q28504693 | ||
| Discovery of antivirals against smallpox | Q28770151 | ||
| Antibiotic policies and control of resistance. | Q30331198 | ||
| Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera | Q31905797 | ||
| Enteropathogenic E. coli Tir binds Nck to initiate actin pedestal formation in host cells | Q33292526 | ||
| Vaccinia virus intracellular movement is associated with microtubules and independent of actin tails | Q33849999 | ||
| Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor | Q33912043 | ||
| Surfing pathogens and the lessons learned for actin polymerization. | Q34123309 | ||
| The formation and function of extracellular enveloped vaccinia virus | Q34162719 | ||
| SRC mediates a switch from microtubule- to actin-based motility of vaccinia virus | Q34339142 | ||
| Cell transformation by the middle T-antigen of polyoma virus | Q34468798 | ||
| Ras family GTPases control growth of astrocyte processes | Q34625170 | ||
| Mapping and functional analysis of interaction sites within the cytoplasmic domains of the vaccinia virus A33R and A36R envelope proteins | Q34781856 | ||
| Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome | Q35186302 | ||
| Vaccinia virus motility | Q35550578 | ||
| Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. | Q36496450 | ||
| Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene | Q36765625 | ||
| Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. | Q37031466 | ||
| Molecular themes in oncogenesis | Q37625792 | ||
| Enteropathogenic E. coli acts through WASP and Arp2/3 complex to form actin pedestals | Q39254264 | ||
| Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections | Q40666918 | ||
| The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases | Q40684182 | ||
| Chronic myeloid leukemia: current treatment options | Q40685296 | ||
| Grb2 and Nck act cooperatively to promote actin-based motility of vaccinia virus | Q40732614 | ||
| Autoinhibition of c-Abl | Q40752403 | ||
| Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread | Q40761451 | ||
| Vaccinia virus utilizes microtubules for movement to the cell surface. | Q40790144 | ||
| Antibody neutralization of the extracellular enveloped form of vaccinia virus | Q40829727 | ||
| Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread | Q41044354 | ||
| Neutralizing epitope on penetration protein of vaccinia virus | Q41191411 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| P304 | page(s) | 731-739 | |
| P577 | publication date | 2005-06-26 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases | |
| P478 | volume | 11 |
| Q56786373 | A guided tour through the antiviral drug field |
| Q42062623 | A role for the small GTPase Rac1 in vaccinia actin-based motility |
| Q38543088 | A role for the small GTPase Rac1 in vaccinia actin-based motility |
| Q27335617 | A36-dependent actin filament nucleation promotes release of vaccinia virus |
| Q40324208 | Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus |
| Q40338662 | Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus |
| Q39885253 | An E2-F12 complex is required for intracellular enveloped virus morphogenesis during vaccinia infection |
| Q30358429 | Antiviral agents active against influenza A viruses. |
| Q30231576 | Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection |
| Q80162607 | Antivirals become a broader enterprise |
| Q89795210 | Antivirals in medical biodefense |
| Q56786312 | Antivirals: current state of the art |
| Q30572619 | Arp2/3-mediated actin-based motility: a tail of pathogen abuse |
| Q27473132 | Attacking pathogens through their hosts |
| Q39637771 | Back to the future: host-targeted chemotherapeutics for drug-resistant TB. |
| Q35894355 | Basigin is a druggable target for host-oriented antimalarial interventions |
| Q41809063 | Bortezomib inhibits hepatitis B virus replication in transgenic mice |
| Q89555204 | Bridging the Gap: Virus Long-Distance Spread via Tunneling Nanotubes |
| Q39419652 | Casein kinase 2 regulates vaccinia virus actin tail formation |
| Q54693056 | Cell biology. Propelling progeny. |
| Q35260385 | Development of ST-246® for Treatment of Poxvirus Infections |
| Q37828538 | Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses |
| Q40325552 | Divergent roles of β- and γ-actin isoforms during spread of vaccinia virus |
| Q34027426 | Emerging drugs for varicella-zoster virus infections |
| Q60955970 | Enteropathogenic E. coli relies on collaboration between the formin mDia1 and the Arp2/3 complex for actin pedestal biogenesis and maintenance |
| Q36438769 | Exploiting pathogenic Escherichia coli to model transmembrane receptor signalling |
| Q33521248 | F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection |
| Q36688935 | First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy |
| Q36716750 | Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs |
| Q46599051 | Gleevec casts a pox on poxviruses |
| Q40600058 | Guidelines for vaccination of immunocompromised individuals |
| Q36065201 | Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase |
| Q38617932 | Historical perspectives in the development of antiviral agents against poxviruses |
| Q38489473 | Host-Directed Therapies for Tuberculosis. |
| Q56763206 | Human Poxviruses |
| Q36498115 | Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation |
| Q33351233 | Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach |
| Q39331272 | Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis |
| Q34046541 | Immunological off-target effects of imatinib |
| Q35772104 | In vitro inhibition of monkeypox virus production and spread by Interferon-β. |
| Q37384933 | Induction of cell-cell fusion by ectromelia virus is not inhibited by its fusion inhibitory complex |
| Q39648951 | Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid |
| Q42212627 | Initial characterization of vaccinia virus B4 suggests a role in virus spread |
| Q43288824 | Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective |
| Q52365425 | Loss of Actin-Based Motility Impairs Ectromelia Virus Release In Vitro but Is Not Critical to Spread In Vivo. |
| Q36155569 | Loss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo |
| Q27320733 | Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity |
| Q26771277 | Multifunctional Abl kinases in health and disease |
| Q27325801 | Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesis |
| Q40527122 | NPF motifs in the vaccinia virus protein A36 recruit intersectin-1 to promote Cdc42:N-WASP-mediated viral release from infected cells |
| Q30371980 | New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics |
| Q33769835 | Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. |
| Q37845399 | Oncolytic vaccinia virus for the treatment of cancer |
| Q35635226 | Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells |
| Q37593480 | Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012. |
| Q37173398 | Orthopoxvirus targets for the development of new antiviral agents. |
| Q56786253 | Outlook of the Antiviral Drug Era, Now More Than 50 Years after Description of the First Antiviral Drug |
| Q35663339 | Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses |
| Q42974816 | Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system |
| Q37960427 | Phosphorylation events during viral infections provide potential therapeutic targets. |
| Q59793441 | Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents |
| Q33743876 | Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination |
| Q36694985 | Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase |
| Q37331541 | Progress in the discovery of compounds inhibiting orthopoxviruses in animal models |
| Q28472290 | RNAi screen reveals an Abl kinase-dependent host cell pathway involved in Pseudomonas aeruginosa internalization |
| Q45324172 | Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection. |
| Q38771653 | Remodeling of the fibroblast cytoskeletal architecture during the replication cycle of Ectromelia virus: A morphological in vitro study in a murine cell line |
| Q38201237 | Rho'ing in and out of cells: viral interactions with Rho GTPase signaling |
| Q39321282 | RhoA-GTPase facilitates entry of Kaposi's sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner |
| Q54977170 | Role of MAPK/MNK1 signaling in virus replication. |
| Q37746052 | Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs |
| Q37051663 | SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system |
| Q28086933 | SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function |
| Q39446284 | SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral |
| Q57179579 | Septins suppress the release of vaccinia virus from infected cells |
| Q35086690 | Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy |
| Q36480688 | Signaling during pathogen infection |
| Q36441506 | Smallpox antiviral drug development: satisfying the animal efficacy rule |
| Q91908886 | Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses |
| Q43922693 | Surfing through a sea of sharks: report on the British Society for Cell Biology meeting on 'Signaling and Cytoskeletal Dynamics During Infection', October 2-5, 2005, Edinburgh, Scotland |
| Q34698954 | Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues |
| Q35091855 | Systematic approaches towards the development of host-directed antiviral therapeutics |
| Q36520749 | Systems biology of virus entry in mammalian cells |
| Q34243476 | Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus |
| Q38192567 | Systems kinomics for characterizing host responses to high-consequence pathogens at the NIH/NIAID Integrated Research Facility-Frederick |
| Q34909902 | Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer |
| Q36973195 | Targeting Drug-Sensitive and -Resistant Strains of Mycobacterium tuberculosis by Inhibition of Src Family Kinases Lowers Disease Burden and Pathology |
| Q28594369 | The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection |
| Q34992596 | The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics |
| Q78177468 | The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases. |
| Q40630924 | The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection. |
| Q38089868 | The design and development of drugs acting against the smallpox virus. |
| Q35077647 | The host phosphoinositide 5-phosphatase SHIP2 regulates dissemination of vaccinia virus |
| Q38135838 | The non-canonical roles of clathrin and actin in pathogen internalization, egress and spread |
| Q39877031 | The rate of N-WASP exchange limits the extent of ARP2/3-complex-dependent actin-based motility |
| Q38355488 | The role of signalling and the cytoskeleton during Vaccinia Virus egress |
| Q30603690 | The serine/threonine kinase STK11 promotes Shigella flexneri dissemination through establishment of cell-cell contacts competent for tyrosine kinase signaling |
| Q91644903 | The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function |
| Q37009973 | Therapeutic and prophylactic drugs to treat orthopoxvirus infections |
| Q33857450 | There is an A33-dependent mechanism for the incorporation of B5-GFP into vaccinia virus extracellular enveloped virions |
| Q34984243 | Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure |
| Q91760373 | Toxoplasma gondii induces prolonged host epidermal growth factor receptor signalling to prevent parasite elimination by autophagy: Perspectives for in vivo control of the parasite |
| Q26864729 | Tuberculosis drug discovery in the post-post-genomic era |
| Q28475302 | Unc119 protects from Shigella infection by inhibiting the Abl family kinases |
| Q94502757 | Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment |
| Q27315837 | Vaccinia protein F12 has structural similarity to kinesin light chain and contains a motor binding motif required for virion export |
| Q39552891 | Vaccinia virus dissemination requires p21-activated kinase 1. |
| Q37201070 | Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis |
| Q60913456 | Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics |
| Q34457869 | Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases |
| Q35274610 | Variola virus F1L is a Bcl-2-like protein that unlike its vaccinia virus counterpart inhibits apoptosis independent of Bim. |
| Q36392210 | Viral interactions with the cytoskeleton: a hitchhiker's guide to the cell |
| Q37726587 | Virus cell-to-cell transmission. |
| Q30944807 | Virus movements on the plasma membrane support infection and transmission between cells |
| Q40531470 | Viruses That Exploit Actin-Based Motility for Their Replication and Spread |
| Q30009849 | WIP provides an essential link between Nck and N-WASP during Arp2/3-dependent actin polymerization |
| Q40132445 | Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs |
Search more.